Navigation Links
Controversial vaccine trial should never have been run in India, researchers say
Date:6/20/2012

Research published today in the Journal of the Royal Society of Medicine raises further questions about a trial of HPV vaccines in India.

The trial, which has now been halted and is the subject of an investigation by the Indian government, was examining the safety and feasibility of offering a vaccine against the virus associated with cervical cancer.

The new study by researchers at Queen Mary, University of London and the University of Edinburgh suggests that lack of data on cervical cancer in India does not support a trial of the vaccine to prevent the disease.

The trial was run by the international health charity PATH and involved more than 23,000 girls from Gujarat and Andhra Pradesh states. A committee of scientists commissioned by the Indian Government to look into the trial said that the study involved a number of serious ethical violations.

The research by Professor Allyson Pollock and colleagues examined a series of claims made by PATH about cervical cancer in India, among them that 'in raw numbers, India has the largest burden of cancer of the cervix of any country worldwide'.

They found that cancer surveillance, registration and monitoring in India in general - and specifically in the Gujarat and Andhra Pradesh regions - was incomplete, meaning that it would be impossible to tell whether the vaccine would be successful in preventing the disease.

In addition, figures that do exist for India show that incidence rates for cervical cancer are low and fell from around 43 cases per 100,000 in 1982/83 to around 22 per 100,000 in 2004/05. Brazil and Zimbabwe are reported to have around twice the rate.

Professor Pollock explained: "This trial has clearly raised serious concerns for the people and government of India. The aim of our study was to look at whether data on cervical cancer in the country justify the introduction of HPV vaccination.

"We found that current data on cervical cancer incidence do not support PATH's claim that India has a large burden of cervical cancer or its decision to roll out the vaccine programme.

"The lack of information is important because it means that World Health Organisation criteria for monitoring the effectiveness of the vaccine cannot be fulfilled.

"Neither the epidemiological evidence nor current cancer surveillance systems justify the general rollout ofan HPV vaccination programme in India or in the two states where PATH was conducting its research."

Professor Pollock continued: "It's important to compare the burden of cervical cancer in India to other major health concerns, such as primary care, malaria, maternal anaemia and malnutrition, and consider best use of financial resources.

"HPV vaccine which is among the most expensive vaccines on the market is not justified as a health care priority for India."


'/>"/>
Contact: Kerry Noble
k.noble@qmul.ac.uk
44-020-788-27943
Queen Mary, University of London
Source:Eurekalert

Related medicine news :

1. U.S. Gives Green Light to Publish Controversial Bird Flu Research
2. Study Suggests Vaccine May Help Kids With Brain Cancer
3. Young girls more likely to report side effects after HPV vaccine
4. Preteens More Likely to Report HPV Vaccine Side Effects
5. Vaccine yielded encouraging long-term survival rates in certain patients with NSCLC
6. Early Study Finds Some Promise for Lung Cancer Vaccine
7. From a Failed Vaccine, New Insights Into Fighting HIV
8. From herd immunity and complacency to group panic: How vaccine scares unfold
9. Brain Tumor Vaccine Shows Promise in Early Trial
10. Army researcher develops potential vaccine carrier
11. A physicians guide for anti-vaccine parents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2020)... ... May 21, 2020 , ... A new report ... Group, details over 90 companies involved in the point of care test industry. ... for preliminary testing, COVID-19 has made point-of-care more important than in the past, according ...
(Date:5/17/2020)... ... 2020 , ... R3 Stem Cell International is now offering ... are two program options for patients and their families, which are all inclusive ... exactly what causes Autism Spectrum Disorder (ASD), there are several recent clinical studies ...
(Date:5/16/2020)... (PRWEB) , ... May 15, 2020 , ... On May 21, T1V will host a ... Ellison Institute of USC, and a contributor to CBS news, as we address COVID-19 and ... place in most parts of the country since March, many questions are left unanswered as ...
(Date:5/16/2020)... HOWELL, Mich. (PRWEB) , ... May 16, 2020 , ... ... be caught relatively early, this will prevent permanent arthritis from developing. This can keep ... , Dr. Biernacki further states “It is estimated that the people who develop flat ...
(Date:5/15/2020)... ... May 15, 2020 , ... Collagen has taken the ... natural channel alone in 2019, according to a 2020 Nutritional Outlook ‘Ingredients to Watch’ ... further and further away from the high molecular weight, low-impact products of the past ...
Breaking Medicine News(10 mins):
(Date:5/14/2020)... (PRWEB) , ... May 14, 2020 , ... ... discuss sEMG Biofeedback as an effective intervention tool in neuro-rehabilitation. sEMG Biofeedback is ... will show the immediate effect of using biofeedback to create awareness and efficient ...
(Date:5/14/2020)... ... 2020 , ... Northern Quinoa Production Corporation ( NorQuin ) ... ingredient suppliers, Ingredion Incorporated , which will distribute NorQuin's high-value ... , NorQuin has invested more than two decades of research to ...
(Date:5/11/2020)... ... May 11, 2020 , ... ... people worldwide. Recommendations to improve immunity often include social distancing, enhanced hygiene, adequate ... Michael T. Murray, N.D., also stresses the importance of digestive enzymes in boosting ...
Breaking Medicine Technology: